$273 Million is the total value of Omega Fund Management, LLC's 19 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 42.9% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
REPL | Sell | Replimune Group | $74,056,000 | -9.3% | 4,288,154 | -8.2% | 27.12% | +4.0% |
NUVB | Sell | Nuvation Bio | $33,762,000 | -31.7% | 15,072,340 | -1.1% | 12.36% | -21.6% |
Sell | Cincor Pharma | $18,412,000 | +1.1% | 560,985 | -41.9% | 6.74% | +16.1% | |
MORF | Sell | Morphic Holding | $16,916,000 | -22.9% | 597,723 | -40.9% | 6.20% | -11.5% |
IMCR | Exit | Immunocore Holdingsads | $0 | – | -51,535 | -100.0% | -0.61% | – |
SYRS | Exit | Syros Pharmaceuticals | $0 | – | -2,512,705 | -100.0% | -0.77% | – |
ARQT | Exit | Arcutis Biothereapeutics | $0 | – | -623,836 | -100.0% | -4.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
Replimune Group | 21 | Q3 2023 | 47.2% |
Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
Morphic Holding | 18 | Q3 2023 | 22.0% |
Immunic Inc | 18 | Q3 2023 | 9.0% |
Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-14 |
13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.